- Emerge
- Posts
- 🚀 Home Depot Beats Earnings Expectations
🚀 Home Depot Beats Earnings Expectations
Want to get the most out of ChatGPT?
ChatGPT is a superpower if you know how to use it correctly.
Discover how HubSpot's guide to AI can elevate both your productivity and creativity to get more things done.
Learn to automate tasks, enhance decision-making, and foster innovation with the power of AI.
Market Overview
Read time 1.4 minutes
Year To Date Performances:
Dow Jones | 43,461.21 | 2.16% |
S&P 500 | 5,983.25 | 1.73% |
Nasdaq | 19,286.93 | -0.12% |
Russell 2000 | 2,178.27 | -2.33% |
TSX | 25,151.26 | 1.71% |
Bitcoin | $89,236.94 | -3.41% |
Ethereum | $2,435.71 | -26.86% |
US to Canadian Dollar | $1.42 | -1.01% |
Home Depot beat Wall Street's Q4 expectations, reporting EPS of $3.02 vs. $3.01 expected and revenue of $39.7B vs. $39.16B expected. The retailer ended an eight-quarter streak of declining comparable sales, posting a 0.8% increase, with U.S. sales up 1.3%. However, challenges remain, as high mortgage rates and home prices continue to dampen demand for major renovations. Online sales rose 9%, and Home Depot plans to open 13 new stores in 2025, expanding its footprint and professional customer base. Despite the earnings beat, shares fell 2% in premarket trading.
Eli Lilly is expanding access to its weight loss drug Zepbound by offering higher-dose single-use vials at lower prices through its LillyDirect platform. The company aims to reach patients without insurance coverage, including Medicare recipients, by pricing 7.5mg and 10mg vials at $499 for first-time prescriptions (or $599 and $699 for later refills). These vials require patients to self-inject using syringes, making them cheaper and easier to produce than the $1,000/month autoinjector pens. With FDA-approved supplies increasing, Lilly hopes to steer patients away from compounded versions and push for Medicare coverage of obesity drugs under Trump’s administration.
Bitcoin fell 5% to $89,122, briefly dipping to $87,736, as selling pressure from equities weighed on the crypto market. The decline puts BTC nearly 20% below its all-time high, with analysts attributing the drop to macroeconomic uncertainty and a lack of new catalysts following Trump’s crypto-friendly executive order in January. If Bitcoin breaks below the $90K support level, analysts warn of a potential pullback to $70K-$75K, though many expect a rebound by mid-March. Broader crypto markets also suffered, with Ether and Solana down 9% and the CoinDesk 20 index losing 8%.
Headlines
Trump has reaffirmed his intention to move forward with tariffs on Canada and Mexico next month.
Elon Musk has doubled down on his threat to fire all workers who don’t file their list of accomplishments from last week after entire departments refused to comply with his request.
* This is sponsored content.
Are you looking to grow your business? Here is how I can help:
📱Book a Strategy Call to get 1:1 feedback on your pitch, pitch deck and/or fundraising strategy. (If you need general startup advice, then reply to this email, and I’ll let you know if/how I can help.)
There’s a reason 400,000 professionals read this daily.
Join The AI Report, trusted by 400,000+ professionals at Google, Microsoft, and OpenAI. Get daily insights, tools, and strategies to master practical AI skills that drive results.
Onwards and Upwards,

|